Atherosclerosis: Open Access
Open Access

Hong Yin

Amgen Biopharmaceutical Research & Development (Shanghai) Co., Ltd, Shanghai, China 4F, Building 6, 99 Haike Road, Shanghai, 201210, PR China

Biography

Hong Yin is the member of Amgen Biopharmaceutical Research & Development (Shanghai) Co., Ltd, Shanghai, China. 
He is board certified in Internal Medicine, Cardiovascular Disease, Interventional Cardiology and Endovascular Medicine. Hong Yin is a member of multiple professional societies.

Publications

Prevalence and Outcomes of Familial Hypercholesterolemia Patients in a Chinese Myocardial Infarction Cohort

Background and aims: Familial Hypercholesterolemia (FH) is an inherited metabolic disorder with increased LDL-C levels and coronary heart disease (CHD) risk. The prevalence of heterozygous FH is approximately 1:200 to 1:500 worldwide and higher in CHD populations. We aim to estimate the prevalence of FH and the incidence of recurrent cardiovascular... Read More»

Yan Gao, Hong Yin, Ying He, Jihua Wu, Siming Wang, Wenjin Li, Xi Li, Ouhong Wang, Mingqiang Zhang and Lixin Jiang

Research Article: Atheroscler Open Access 2017, 2:114

Abstract Peer-reviewed Full Article Peer-reviewed Article PDF Mobile Full Article

Global Experts in the subject